SMi’s 20th Annual Pain Therapeutics Conference
Discover Cutting Edge Research and Novel Therapeutics in the Pipeline

Conference: 11 and 12 May 2020
Location: REMOTE ACCESS ONLY
Website: http://www.pain-therapeutics.co.uk/PharmaJournWL

Announcement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.pain-therapeutics.co.uk

The price to be a part of this conference is £999 (remote access) and registration is available via the conference website at www.pain-therapeutics.co.uk

The 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals.

This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment. 

Presentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors. Furthermore, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs. 

Join SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

Event Hashtag: #SMiPain

View the full agenda: http://www.pain-therapeutics.co.uk/PharmaJournWL

WHO SHOULD ATTEND

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

• Pain and Migraine
• Inflammation
• Chronic Pain
• Neuropathic Pain
• Analgesic pre-clinical development
• Anaesthesia and Pain Management
• CNS clinical trials
• Ion Channel Pharmacology
• Pharmacology Intelligence
• Translational science
• Drug development
• Exploratory development

EARLY BIRD-RATES

• BOOK BY 28TH FEBRUARY AND SAVE £200
• BOOK BY 31ST MARCH AND SAVE £100